Adocia (ADOC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Adocia (ADOC) has a cash flow conversion efficiency ratio of 1.826x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€2.72 Million ≈ $3.18 Million USD) by net assets (€1.49 Million ≈ $1.74 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Adocia to measure how much of total assets are equity-financed.
Adocia - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Adocia's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ADOC operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Adocia Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adocia ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GnBS Engineering Co. Ltd.
KQ:382800
|
0.162x |
|
Manoj Vaibhav Gems 'N' Jewellers Limited
NSE:MVGJL
|
0.128x |
|
COMMERCIAL SYN BAGS ORD (BSE)
NSE:COMSYN
|
0.024x |
|
Verrica Pharmaceuticals Inc
NASDAQ:VRCA
|
-0.571x |
|
La Kaffa International Co Ltd
TWO:2732
|
0.106x |
|
Indorama Synthetics Tbk
JK:INDR
|
0.014x |
|
Maeil Holdings Co. Ltd
KQ:005990
|
0.032x |
|
CeoTronics AG
F:CEK
|
0.061x |
Annual Cash Flow Conversion Efficiency for Adocia (2010–2025)
The table below shows the annual cash flow conversion efficiency of Adocia from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Adocia.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.49 Million ≈ $1.74 Million |
€-6.53 Million ≈ $-7.63 Million |
-4.380x | -186.66% |
| 2024-12-31 | €-3.09 Million ≈ $-3.61 Million |
€-15.61 Million ≈ $-18.25 Million |
5.054x | +605.94% |
| 2023-12-31 | €-6.91 Million ≈ $-8.08 Million |
€-4.95 Million ≈ $-5.79 Million |
0.716x | -38.08% |
| 2022-12-31 | €-12.97 Million ≈ $-15.16 Million |
€-14.99 Million ≈ $-17.53 Million |
1.156x | -16.95% |
| 2021-12-31 | €-13.81 Million ≈ $-16.15 Million |
€-19.23 Million ≈ $-22.49 Million |
1.392x | +140.35% |
| 2020-12-31 | €6.33 Million ≈ $7.41 Million |
€-21.85 Million ≈ $-25.55 Million |
-3.450x | -902.03% |
| 2019-12-31 | €28.04 Million ≈ $32.78 Million |
€-9.65 Million ≈ $-11.29 Million |
-0.344x | -350.07% |
| 2018-12-31 | €45.85 Million ≈ $53.60 Million |
€6.31 Million ≈ $7.38 Million |
0.138x | +122.83% |
| 2017-12-31 | €36.86 Million ≈ $43.09 Million |
€-22.23 Million ≈ $-25.99 Million |
-0.603x | -96.29% |
| 2016-12-31 | €42.76 Million ≈ $49.99 Million |
€-13.14 Million ≈ $-15.36 Million |
-0.307x | -132.56% |
| 2015-12-31 | €47.05 Million ≈ $55.01 Million |
€-6.22 Million ≈ $-7.27 Million |
-0.132x | -101.08% |
| 2014-12-31 | €2.50 Million ≈ $2.93 Million |
€30.56 Million ≈ $35.73 Million |
12.200x | +2261.78% |
| 2013-12-31 | €19.13 Million ≈ $22.36 Million |
€-10.80 Million ≈ $-12.62 Million |
-0.564x | -1514.13% |
| 2012-12-31 | €23.03 Million ≈ $26.92 Million |
€919.00K ≈ $1.07 Million |
0.040x | +102.78% |
| 2011-12-31 | €4.33 Million ≈ $5.06 Million |
€-6.22 Million ≈ $-7.27 Million |
-1.436x | -209.61% |
| 2010-12-31 | €10.69 Million ≈ $12.49 Million |
€-4.96 Million ≈ $-5.79 Million |
-0.464x | -- |
About Adocia
Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of act… Read more